The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Employment - Genentech; Gilead Sciences
Stock and Other Ownership Interests - Genentech

Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer.
Hope S. Rugo
Honoraria - Mylan; Puma Biotechnology; Samsung Bioepis
Consulting or Advisory Role - Napo Pharmaceuticals
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Sermonix Pharmaceuticals (Inst)
Aditya Bardia
Consulting or Advisory Role - bioTheranostics; Daiichi Sankyo/Astra Zeneca; Foundation Medicine; Genentech; Genentech/Roche (Inst); Immunomedics; Immunomedics (Inst); Innocrin Pharma (Inst); Merck; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Philips Healthcare; Puma Biotechnology; Radius Health; Radius Health (Inst); Sanofi; Spectrum Pharmaceuticals
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst)
Frederik Marmé
Honoraria - Agendia; Amgen; AstraZeneca; Celgene; Clovis Oncology; Eisai; Genomic Health; Gilead Sciences; GlaxoSmithKline; Immunomedics; Lilly; MSD Oncology; Myriad Genetics; Novartis; Pfizer; PharmaMar; Pierre Fabre; Roche/Genentech; Seattle Genetics; Tesaro
Consulting or Advisory Role - Amgen; AstraZeneca; CureVac; Eisai; Genomic Health; Gilead Sciences; GlaxoSmithKline; Immunomedics; Pfizer; Roche; Tesaro; Vaccibody
Research Funding - AstraZeneca; Clovis Oncology; Gilead Sciences; GlaxoSmithKline; MSD Oncology; Novartis; Roche/Genentech; Tesaro; Vaccibody
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
Javier Cortes
Stock and Other Ownership Interests - Leuko (I); MedSIR; Nektar
Honoraria - Celgene; Daiichi Sankyo; Eisai; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung
Consulting or Advisory Role - AstraZeneca; Athenex; Bioasis; Bioinvent; Boehringer Ingelheim; Celgene; Cellestia Biotech; Clovis Oncology; Daiichi Sankyo; Ellipses Pharma; ERYTECH Pharma; GEMoaB; Gilead Sciences; GlaxoSmithKline; HiberCell; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Reveal Genomics; Roche; Seattle Genetics; SERVIER; Zymeworks
Research Funding - ARIAD (Inst); Astrazeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A.
Travel, Accommodations, Expenses - Daiichi Sankyo; Eisai; Gilead Sciences; Novartis; Pfizer; Roche
Peter Schmid
Employment - Roche (I)
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Merck; Novartis; Pfizer; Puma Biotechnology; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation; Novartis (Inst); Oncogenex (Inst); Roche (Inst)
Delphine Loirat
Honoraria - Amgen; AstraZeneca Canada; Eisai; Gilead Sciences; Lilly; MSD; Novartis
Consulting or Advisory Role - 4D Pharma; Amgen; AstraZeneca; Daiichi Sankyo; Eisai; Immunomedics; Lilly; MSD; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Gilead Sciences; MSD; Novartis; Pfizer; Roche
Olivier Tredan
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Europe GmbH; Eisai Europe; Gilead Sciences; Lilly; MSD Oncology; Pfizer; Pierre Fabre; Pierre Fabre; Roche; Sandoz-Novartis; Seattle Genetics
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Eva Ciruelos
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Lilly; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Lilly; Pfizer
Travel, Accommodations, Expenses - Pfizer; Roche
Florence Dalenc
No Relationships to Disclose
Patricia Gómez Pardo
No Relationships to Disclose
Komal L. Jhaveri
Consulting or Advisory Role - Abbvie; AstraZeneca; Biotheranostics; BluePrint Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Intellisphere; Jounce therapeutics; Lilly; Novartis; Pfizer; Sanofi; Seattle Genetics; Sun Pharma Advanced Research Company; Synthon; Taiho Oncology
Research Funding - ADC Therapeutics (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); Pfizer (Inst); Puma Biotechnology (Inst); VelosBio/Merck (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Intellisphere; Jounce Therapeutics; Pfizer; Taiho Pharmaceutical
Rosemary Delaney
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
Olivia Fu
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
Lanjia Lin
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
Wendy Verret
No Relationships to Disclose
Sara M. Tolaney
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Athenex; BeyondSpring Pharmaceuticals; Blueprint Medicines; Bristol-Myers Squibb; Certara Inc; Chugai Pharma; CytomX Therapeutics; Daiichi Sankyo; Eisai; Ellipses Pharma; G1 Therapeutics; Genentech; Immunomedics/Gilead; Infinity Pharmaceuticals; Kyowa Hakko Kirin; Lilly; Merck; Mersana; NanoString Technologies; Nektar; Novartis; Odonate Therapeutics; OncoPep; OncoSec; OncXerna Therapeutics; Paxman; Pfizer; Puma Biotechnology; Reveal Genomics; Samsung Bioepis; Sanofi; Seattle Genetics; Zentalis; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Nektar (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Sanofi (Inst); Seattle Genetics (Inst)